PAHO HPV Test Deals Cut Cervical Screening Costs

Millions of women across Latin America and the Caribbean will gain access to more affordable, high-quality human papillomavirus (HPV) testing under landmark regional agreements negotiated by the Pan American Health Organization (PAHO).
The first-ever region-wide access agreements, announced on 11 November 2026, were negotiated by PAHO through its Regional Revolving Funds, with support from the global health agency Unitaid.
Savings of 30 to 70 per cent
Under the agreements, countries will be able to buy high-quality molecular HPV tests at preferential prices, along with a comprehensive support package. Participating countries are expected to realise cost savings ranging from 30 per cent to 70 per cent.
The arrangements expand the range of World Health Organization-recommended molecular HPV testing technologies available through PAHO's Revolving Funds, under harmonised regional conditions for all countries and territories in Latin America and the Caribbean.
PAHO has recommended HPV testing in cervical cancer screening programmes since 2013, with updated guidance issued in 2026. So far, 16 countries and territories in the region have introduced HPV testing in their screening programmes, although coverage has been limited by the high cost of the tests.
Rollout in five countries first
Unitaid will support implementation in five countries in particular: El Salvador, Guatemala, Grenada, Saint Vincent and the Grenadines, and Saint Lucia. The work will help those countries introduce or expand HPV-based screening programmes and strengthen follow-up care for women who test positive.
Evidence from the ESTAMPA study, conducted across several Latin American countries and published in The Lancet Regional Health - Americas, has supported the use of HPV testing as the primary screening method for cervical cancer.
The initiative is part of PAHO's Disease Elimination Initiative, which seeks to eliminate more than 30 diseases and related conditions in the Americas, including cervical cancer. It also supports the World Health Organization's global cervical cancer elimination strategy, which sets 90-70-90 targets for 2030: 90 per cent of girls vaccinated against HPV, 70 per cent of women screened, and 90 per cent of women with cervical disease treated.
The deals work through PAHO's Regional Revolving Funds, which use the collective purchasing power of member states to negotiate lower prices for vaccines, medicines and diagnostics. By buying together under harmonised regional conditions, smaller countries gain access to the same preferential pricing as larger ones, breaking down the financial barriers that have kept modern diagnostic tools out of reach for millions of women in low- and middle-income countries.
Dr Philippe Duneton, executive director of Unitaid, said the initiative extended favourable pricing to countries across the region, and Unitaid's support will help turn the agreements into screening programmes that reach women, rather than prices on paper.